UNLOCKING THE FUTURE OF LIQUID BIOPSY RESEARCH
Liquid biopsy research can revolutionize the way we detect, diagnose, and treat diseases. However, several issues need to be resolved before it can reach its full potential.
Access to relevant specimens is an essential part of any discovery and development research program, but the complexity and cost associated with procuring these samples can be daunting. While no universal standard for liquid biopsy biobanking exists, there are known collection conditions that can influence analytical variability and reduce the risk of failure rates.
Further, validation of molecular biomarkers requires access to a heterogeneous cohort of disease-state and control donors to support clinical utility. To unlock the full potential of liquid biopsy research, it is important to have standardized collection protocols and a diverse donor base to develop more accurate models that will translate to better decisions in healthcare.
Key topics that will be discussed in this webinar include:
- Biobanking requirements to facilitate and support liquid biopsy research
- Considerations for specimen collections to minimize pre-analytical variability
- Importance of a diverse donor base to comprehensively investigate molecular biomarkers
About the Presenter
Courtney Noah, PhD, is BioIVT's Vice President of Scientific Affairs. She leads a team that provides solutions for BioIVT’s clients and business partners. With a broad knowledge of life science applications and a keen understanding of business strategy, Dr. Noah has successfully expanded BioIVT's portfolio and increased brand awareness. Previously, Dr. Noah served as BioIVT's head of marketing and director of research and development for the cell and gene therapy business unit. She was also a senior marketing manager for Enzo Life Sciences and a senior scientist at Pall Corporation. Dr. Noah received her PhD in Molecular and Cellular Biology from Stony Brook University, and her BS is in Food Science from Cornell University.